A Phase 3 interventional study of Apremilast and Placebo in Psoriasis, sponsored by Amgen. Completed at 64 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-29.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.
Among the 44 studies testing apremilast in Psoriasis, this one has the largest enrollment, is one of 6 that started in 2019, is one of 18 in phase 3, and was the 26th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Syeda Sana Zaman · Sites in Pakistan
Ages 18–60 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
Amgen
Ages 18–60 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Zarmeen Khawar · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 595 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 103 across the 44 interventional studies. Of the 34 that completed or were terminated, 26 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
61 studies in Psoriasis by Amgen: 1 open now, 1 under way, none of them phase 3. Of 60 finished, 35 (58%) have results posted.
Among the 61 studies in Psoriasis by Amgen, this one is the 5th largest by enrollment of the 49 interventional ones that give a count, is one of 7 that started in 2019, is one of 32 in phase 3, and was the 47th registered.
Amgen’s Psoriasis studies by the year they started, since 2000.
1 of the studies testing apremilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing apremilast in Psoriasis, from their registry updates:
Among Amgen’s 61 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.
Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.
The study will consist of four phases:
Double-blind Placebo-controlled Phase - Weeks 0 to 16
Apremilast Extension Phase - Weeks 16 to 32
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must satisfy the following criteria to be enrolled in the study:
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16).
Other: Placebo
Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16).
Drug: Apremilast
Eligible participants who completed the placebocontrolled phase entered the extension phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
Drug: Apremilast
Apremilast, oral, twice daily
Placebo, oral, twice daily
Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled Phase
The sPGA is a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 =severe. Scores incorporate an assessment by the Investigator of the severity of the 3 primary signs of the disease: erythema, scaling and plaque elevation. An sPGA response is defined as sPGA score of clear (0) or almost clear (1) and with at least a 2-point reduction from baseline at Week 16.
Time frame: Baseline and Week 16 of the placebo-controlled phase
Percentage of Participants With a ≥ 75 Percent (%) Improvement From Baseline in Affected Body Surface Area (BSA) at Week 16
The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total body surface area).
Time frame: Baseline and Week 16 of the placebo-controlled phase
Change From Baseline in Percentage of Affected BSA at Week 16
The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total body surface area). A negative change from baseline indicates a reduction of affected BSA.
Time frame: Baseline and Week 16 of the placebo-controlled phase
Change From Baseline in Total Psoriasis Area Severity Index (PASI) Score at Week 16
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. A negative change from baseline indicates an improvement of disease symptoms.
Time frame: Baseline and Week 16 of the placebo-controlled phase
Percentage of Participants Who Achieved BSA ≤ 3% for Participants With Baseline Affected BSA > 3% at Week 16
The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total body surface area).
Time frame: Baseline and Week 16 of the placebo-controlled phase
Percentage of Participants With ≥ 4-point Reduction From Baseline in Whole Body Itch Numeric Rating Scale (NRS) Score at Week 16 Who Had Baseline Whole Body Itch NRS ≥ 4
The whole body itch NRS is a self-reported measure where participants were asked to assess whole body itch and select a number on a scale of 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch. A reduction in score from baseline represents an improvement in symptoms.
Time frame: Baseline and Week 16 of the placebo-controlled phase
Percentage of Participants With a Scalp Physician Global Assessment (ScPGA) Response at Week 16 Among Participants With Baseline scPGA Score ≥ 2 at Week 16
The ScPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an Investigator's assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation of the overall scalp. An ScPGA response is defined as and ScPGA score clear (0) or almost clear (1) with at least a 2-point reduction from baseline among participants with a baseline ScPGA score ≥ 2.
Time frame: Baseline and Week 16 of the placebo-controlled phase
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
The DLQI is a 10 item questionnaire dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from 0 (not at all) to 3 (very much). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No), and if "No," then the subject is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being 0 (not at all), 1 (a little) and 2 (a lot). Total scores have a possible range of 0 to 30, with 30 corresponding to the worst health-related quality of life, and 0 corresponding to the best score. A negative change from baseline indicates an improvement in health-related quality of life scores.
Time frame: Baseline and Week 16 of the placebo-controlled phase
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A TEAE is any AE that occurs following administration of study treatment. Frequency of TEAEs was assessed as well as severity and treatment relatedness. A TEAE was considered severe based on the Investigator's assessment. A TEAE could be severe if it was serious or non-serious, had symptoms causing discomfort or pain, requiring medical or surgical attention or intervention, interfered with activities of daily life and if drug therapy was required.
Time frame: Placebo: Day 1 to Week 16; Apremilast Day 1 to a maximum of Week 32 (plus 4 week safety follow-up)
Participants were enrolled at 61 research centers in the United States and Canada from March 2019 to July 2020.
| Milestone | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Extension Phase: Apremilast 30 mg |
|---|---|---|---|
| Started | 298 | 297 | 0 |
| Received at least 1 dose of treatment | 297 | 297 | 0 |
| Completed | 246 | 258 | 0 |
| Not completed | 52 | 39 | 0 |
| Withdrew: Adverse event | 7 | 7 | 0 |
| Withdrew: Lack of efficacy | 4 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 15 | 13 | 0 |
| Withdrew: Withdrawal by subject | 23 | 18 | 0 |
| Withdrew: Other | 3 | 0 | 0 |
| Milestone | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Extension Phase: Apremilast 30 mg |
|---|---|---|---|
| Started | 0 | 0 | 503 |
| Received at least 1 dose | 0 | 0 | 503 |
| Completed | 0 | 0 | 437 |
| Not completed | 0 | 0 | 66 |
| Withdrew: Adverse event | 0 | 0 | 10 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 20 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 21 |
| Withdrew: Other | 0 | 0 | 3 |
| Withdrew: Other (related to covid-19) | 0 | 0 | 7 |
The sPGA is a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 =severe. Scores incorporate an assessment by the Investigator of the severity of the 3 primary signs of the disease: erythema, scaling and plaque elevation. An sPGA response is defined as sPGA score of clear (0) or almost clear (1) and with at least a 2-point reduction from baseline at Week 16.
| Percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled Phase | 4.1 (1.8 to 6.4) | 21.6 (16.7 to 26.4) |
The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total body surface area).
| Percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants With a ≥ 75 Percent (%) Improvement From Baseline in Affected Body Surface Area (BSA) at Week 16 | 7.4 (4.2 to 10.6) | 33.0 (27.4 to 38.6) |
The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total body surface area). A negative change from baseline indicates a reduction of affected BSA.
| Percentage change of affected BSA | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Change From Baseline in Percentage of Affected BSA at Week 16 | -0.07 ± 0.24 | -3.45 ± 0.24 |
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. A negative change from baseline indicates an improvement of disease symptoms.
| Scores on a scale | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Change From Baseline in Total Psoriasis Area Severity Index (PASI) Score at Week 16 | -0.54 ± 0.20 | -3.47 ± 0.20 |
The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total body surface area).
| Percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants Who Achieved BSA ≤ 3% for Participants With Baseline Affected BSA > 3% at Week 16 | 22.9 (17.4 to 28.4) | 61.0 (54.6 to 67.3) |
The whole body itch NRS is a self-reported measure where participants were asked to assess whole body itch and select a number on a scale of 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch. A reduction in score from baseline represents an improvement in symptoms.
| Percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants With ≥ 4-point Reduction From Baseline in Whole Body Itch Numeric Rating Scale (NRS) Score at Week 16 Who Had Baseline Whole Body Itch NRS ≥ 4 | 18.6 (13.4 to 23.7) | 43.2 (36.9 to 49.5) |
The ScPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an Investigator's assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation of the overall scalp. An ScPGA response is defined as and ScPGA score clear (0) or almost clear (1) with at least a 2-point reduction from baseline among participants with a baseline ScPGA score ≥ 2.
| Percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants With a Scalp Physician Global Assessment (ScPGA) Response at Week 16 Among Participants With Baseline scPGA Score ≥ 2 at Week 16 | 16.6 (11.1 to 22.2) | 44.0 (37.1 to 51.0) |
The DLQI is a 10 item questionnaire dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from 0 (not at all) to 3 (very much). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No), and if "No," then the subject is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being 0 (not at all), 1 (a little) and 2 (a lot). Total scores have a possible range of 0 to 30, with 30 corresponding to the worst health-related quality of life, and 0 corresponding to the best score. A negative change from baseline indicates an improvement in health-related quality of life scores.
| Scores on a scale | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16 | -2.4 ± 0.3 | -5.2 ± 0.3 |
An adverse event (AE) is An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A TEAE is any AE that occurs following administration of study treatment. Frequency of TEAEs was assessed as well as severity and treatment relatedness. A TEAE was considered severe based on the Investigator's assessment. A TEAE could be severe if it was serious or non-serious, had symptoms causing discomfort or pain, requiring medical or surgical attention or intervention, interfered with activities of daily life and if drug therapy was required.
| Participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Apremalist: Placebo-controlled Phase and Extension Phase |
|---|---|---|---|
| Any TEAE | 139 | 195 | 351 |
| Severe TEAE | 2 | 8 | 24 |
| Treatment-related TEAE | 36 | 110 | 186 |
Collected over Placebo: Day 1 to Week 16; Apremilast Day 1 to a maximum of Week 32 (plus 4 week safety follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-controlled Phase: Placebo | 0/296 (0%) | 4/296 (1.4%) | 51/296 (17.2%) |
| Placebo-controlled Phase: Apremilast 30 mg | 0/298 (0%) | 1/298 (0.3%) | 118/298 (39.6%) |
| Apremalist: Placebo-controlled Phase and Extension Phase | 0/544 (0%) | 12/544 (2.2%) | 208/544 (38.2%) |
| Event | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Apremalist: Placebo-controlled Phase and Extension Phase |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/296 | 0/298 | 3/544 |
| Cardiac failure congestiveCardiac disorders | 1/296 | 0/298 | 0/544 |
| Pneumonia pneumococcalInfections and infestations | 1/296 | 0/298 | 0/544 |
| Migraine without auraNervous system disorders | 1/296 | 0/298 | 0/544 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 1/296 | 0/298 | 0/544 |
| Angina pectorisCardiac disorders | 0/296 | 1/298 | 1/544 |
| Myocardial ischaemiaCardiac disorders | 0/296 | 1/298 | 1/544 |
| Cardiac failureCardiac disorders | 0/296 | 0/298 | 1/544 |
| Myocardial infarctionCardiac disorders | 0/296 | 0/298 | 1/544 |
| Abdominal painGastrointestinal disorders | 0/296 | 0/298 | 1/544 |
| Event | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Apremalist: Placebo-controlled Phase and Extension Phase |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 15/296 | 49/298 | 78/544 |
| HeadacheNervous system disorders | 15/296 | 39/298 | 70/544 |
| NauseaGastrointestinal disorders | 13/296 | 38/298 | 69/544 |
| Upper respiratory tract infectionInfections and infestations | 15/296 | 17/298 | 46/544 |
| NasopharyngitisInfections and infestations | 8/296 | 22/298 | 37/544 |
| Age, Continuous(years) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| Mean | 48.3 ± 14.45 | 49.2 ± 14.65 | 48.7 ± 14.55 |
| Sex: Female, Male(Participants) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| Female | 147 | 123 | 270 |
| Male | 151 | 174 | 325 |
| Ethnicity (NIH/OMB)(Participants) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 33 | 31 | 64 |
| Not Hispanic or Latino | 260 | 264 | 524 |
| Unknown or Not Reported | 5 | 2 | 7 |
| Race (NIH/OMB)(Participants) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 7 | 8 |
| Asian | 18 | 15 | 33 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 3 |
| Black or African American | 17 | 14 | 31 |
| White | 257 | 254 | 511 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 5 | 9 |
| Static Physician Global Assessment (sPGA) Score(Participants) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| 2 (mild) | 91 | 91 | 182 |
| 3 (moderate) | 207 | 206 | 413 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Mar 2019 to primary completion in Mar 2020, 11 months.
Results were first posted in May 2021, 1 year 2 months after primary completion. A results delay was requested in Nov 2020.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 11 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast